Clinical Study of Pediatric Acute Liver Failure
Launched by FANSEN ZENG · Mar 18, 2025
Trial Information
Current as of April 29, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
PALF is a seriously life-threatening acute disease with a rapid onset, rapid progression and high mortality rate. Especially under the influence of multiple organ dysfunction syndrome (MODS) or other serious complications, clinical prognosis evaluation and treatment decision-making face great challenges.It aims to accurately evaluate the survival probability or liver transplantation needs of patients based on clinical data and biological indicators, and deeply reveal the impact of different factors on the prognosis of PALF from the perspective of etiology, treatment mode (such as mechanical...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • (1) The age is less than 18 years old; (2) Acute onset (≤8 weeks), no liver disease basis in the past; (3) Biochemical evidence of severe liver injury ; (4) Coagulation dysfunction that cannot be corrected by vitamin K: prothrombin time (PT) ≥15s or international standardized ratio (INR) ≥1.5, and accompanied by hepatic encephalopathy at the same time; or meet any of PT≥20s, INR≥2.0, may not be accompanied by hepatic encephalopathy; (5) Provide complete clinical data and treatment records. (6) Agree to participate in this study and obtain informed consent.
- • Exclusion Criteria:(1) Multiple organ failure caused by non-hepatic diseases; (2) Missing data or incomplete follow-up information.
- • -
About Fansen Zeng
Fansen Zeng is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and enhancing patient care. With a focus on innovative therapeutic solutions, Fansen Zeng collaborates with leading healthcare professionals and research institutions to design and implement rigorous clinical studies. Their expertise spans various therapeutic areas, ensuring adherence to the highest ethical and regulatory standards. By fostering transparency and collaboration, Fansen Zeng aims to facilitate the development of safe and effective treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported